{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-200673","form_type":"8-K","ticker":"FBRX","cik":"0001419041","company_name":"Forte Biosciences, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.991072+00:00","generated_at":"2026-05-31T09:17:19.234846+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Forte Biosciences Q2 net loss $(0.27)/share; FB102 phase 1 done, celiac study starts","bullets":["Net loss per share $(0.27) for Q2 2024 vs $(0.42) for Q2 2023; six-month loss $(0.43) vs $(0.74).","Cash and equivalents $24.5M; operating expenses $12.8M (Q2 2024) vs $9.0M (Q2 2023).","FB102 phase 1 SAD/MAD healthy volunteer study completed with good safety and NK cell reduction.","Forte to initiate celiac disease patient study in Q3 2024; top-line data expected Q2 2025.","G&A expenses surged to $7.1M (Q2 2024) from $1.9M, driven by legal and professional costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-200673","json":"https://secwatch.observer/filing/0001193125-24-200673.json","markdown":"https://secwatch.observer/filing/0001193125-24-200673.md","text":"https://secwatch.observer/filing/0001193125-24-200673.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419041/000119312524200673/0001193125-24-200673-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419041/000119312524200673/d886471d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:17:19.234846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}